Opendata, web and dolomites

TITLY SIGNED

Inhibition of the T-cell receptor signalling pathway for treatment of T-cell lymphoma

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TITLY project word cloud

Explore the words cloud of the TITLY project. It provides you a very rough idea of what is the project "TITLY" about.

perform    cancer    hairpin    researcher    team    bethesda    bruton    de    lymphomas    xenograft    mainly    survival    pharmacological    lines    lymphocyte    salles    small    led    proliferation    peripheral    compounds    provides    share    basic    worldwide    place    treatment    regulatory    bcr    cell    exceeding    rely    global    malignancies    fellowship    la    non    united    inhibitor    vitro    potent    group    named    ie    function    national    granted    10th    louis    receptor    11th    france    vivo    scientifique    came    science    translation    indolent    fruitfully    signalling    branch    centre    dr    accelerated    btk    form    usa    revolutionizing    15    previously    medical    tcr    lyon    rapid    pr    dismal    lymphoma    functional    discovery    screen    approval    transformation    potency    gilles    agencies    prognosis    adaptor    nhl    models    works    ptcl    lymphoid    similarly    shrnas    technic    staudt    kinase    recherche    lab    outgoing    return    mature    tyrosine    rnas    first    barely    therapeutic    inhibitors    hodgkin   

Project "TITLY" data sheet

The following table provides information about the project.

Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.crcl.fr/638-Salles-genestier.crcl.aspx
 Total cost 178˙603 €
 EC max contribution 178˙603 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2014
 Funding Scheme MSCA-IF-GF
 Starting year 2015
 Duration (year-month-day) from 2015-11-01   to  2017-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 178˙603.00
2    United States Department of Health and Human Services US (Washington D.C.) partner 0.00

Map

 Project objective

Non-Hodgkin lymphoma (NHL) is a form of cancer emerging from the transformation of a mature B- or T-cell lymphocyte. NHL is the 11th most common cancer in Europe, and the 10th most common cancer worldwide. Functional evidence of the key role of B-cell receptor (BCR) signalling in B-cell malignancies came mainly from works conducted in Dr Louis Staudt’s lab (National Cancer Institute, Lymphoid Malignancies Branch, Bethesda, USA) where the outgoing phase of the global fellowship would take place. Rapid translation of basic science discovery on the BCR signalling led to the development of a specific inhibitor of a key BCR pathway adaptor named Bruton’s tyrosine kinase (BTK), which was granted for accelerated approval both in United States and Europe by regulatory medical agencies. While the potency of BCR pathway inhibitors is currently revolutionizing the management of B-cell malignancies, peripheral (ie mature) T-cell lymphomas (PTCL) still share a dismal prognosis with a 10-year overall survival barely exceeding 15%. Previous work of the experienced researcher provides strong evidence that PTCL similarly rely on T-cell receptor (TCR) signalling pathway for survival. Targeting this pathway could then lead to discovery of potent therapeutic compounds for PTCL treatment. During the 2 years of the global fellowship, the researcher would first perform a TCR pathway small hairpin RNAs (shRNAs) loss-of-function screen in PTCL cell lines in the group of Dr Louis Staudt where the technic is already available and has been fruitfully applied to B-cell malignancies. Second, the researcher would identify potential pharmacological inhibitors of the previously identified targets both in vitro and in vivo in PTCL cell lines xenograft models. This second phase of the project would take place both among the outgoing team and the return group of Pr Gilles Salles (Centre National de la Recherche Scientifique, Indolent-B-cell Proliferation Branch, Lyon, France).

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TITLY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TITLY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

PaSION (2018)

A longitudinal assessment of treatment experience, symptoms and potential associations with biomarkers in cancer patients undergoing immune checkpoint inhibitor therapy

Read More  

CoCoNat (2019)

Coordination in constrained and natural distributed systems

Read More  

EVENTS (2020)

Affective work-related daily events, and changing characteristics of the work context: New challenges for management practices to deliver employees’ well-being and workplace performance

Read More